Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin
Launched by GALDERMA R&D · Feb 19, 2007
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Different application times of the study treatment were being investigated.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female participants older than 30 years of age.
- • Participants with a photodamage grade of at least 4 on the Griffiths photonumeric scale (symmetrical photodamage on the two target areas)
- • Participants with mottled hyper-pigmentation on the face
- • Participants willing and capable of cooperating to the extent and degree required by the protocol
- • Participants must read the Patient Information Sheet and read and sign the Informed Consent form prior to any study related procedures.
- Exclusion Criteria:
- • Participants who were at risk in terms of precautions, warnings, and contra-indication in the package insert for Metvix
- • Participants with suspected porphyria
- • Participants with specific wash-out period for interfering treatments
- • Participants requiring concurrent treatment that would interfere with study objectives and/or evaluations
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Manchester, , United Kingdom
Madrid, , Spain
Patients applied
Trial Officials
CEM Griffiths
Principal Investigator
Professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials